Skip to main content
Top
Published in: BMC Nephrology 1/2020

Open Access 01-12-2020 | Research article

C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy

Authors: Yue Xing, Lina Li, Yaru Zhang, Fanghao Wang, Dandan He, Youxia Liu, Junya Jia, Tiekun Yan, Shan Lin

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

More and more studies demonstrated that genetic variation at C1GALT1 influences Gd-IgA1 level in IgAN. However, whether the expression of β1, 3-galactosyltransferase (β1, 3Gal-T) was influenced may provide insights into how Gd-IgA1 levels are controlled in IgAN.

Methods

Thirty IgAN patients diagnosed in Tianjin Medical University General Hospital from April to September 2018 and 30 healthy volunteers whose age and gender matched with patients were enrolled in this study. Total Gd-IgA1 levels in plasma were determined by ELISA and C1GALT1 levels were determined by RT-PCR. Four databases (PubMed, EMBASE, CNKI, WanFang Medical Network) were searched to identify eligible studies that evaluated a difference in the expression of C1GALT1 in IgAN patients compared with total controls (non-IgAN and health controls). The C1GALT1C1 expression levels, which was indispensable to β1, 3Gal-T of IgA1, was also been compared.

Results

Gd-IgA1 levels were remarkable higher in IgAN patients compared with healthy control. The expression levels of C1GALT1 gene were remarkably down-regulated in IgAN patients compared with healthy control. And the mRNA level of C1GALT1 was inversely correlated to Gd-IgA1 levels. In meta-analysis, six articles including 316 participants that analyzed the expression of β1, 3Gal-T were met inclusion criteria. There was no significant difference in the expression of C1GALT1 between IgAN patients compared with controls. And we found patients with IgAN had lower levels of C1GALT1 gene expression in the B cells compared to controls. The C1GALT1C1 levels in the IgAN patients were not different from the levels in the control group, which were unchanged no matter according to different ethnic population, different control group and different cell source. Two studies including 46 persons compared enzymatic activity of β1, 3Gal-T in B cells, and the result showed the β1, 3Gal-T activity was decreased in B cells.

Conclusions

We found expression levels of C1GALT1 were remarkably downregulated in IgAN patients and negatively correlated with higher levels of Gd-IgA1. Subsequent meta-analysis validated the low expression and activity of β1, 3Gal-T in B cells in patients with IgAN. However, there was no apparent disparity in the aspect of C1GALT1C1 expression between IgAN and control groups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. J Nephrol. 2016;29(1):13–9.CrossRef Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. J Nephrol. 2016;29(1):13–9.CrossRef
2.
go back to reference Vecchio M, Bonerba B, Palmer SC, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015;8:CD003965. Vecchio M, Bonerba B, Palmer SC, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015;8:CD003965.
3.
go back to reference Gale DP, Molyneux K, Wimbury D, et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158–66.CrossRef Gale DP, Molyneux K, Wimbury D, et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158–66.CrossRef
4.
go back to reference Xiao J, Wang M, Xiong D, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and Cosmc. Mol Med Rep. 2017;15(2):969–74.CrossRef Xiao J, Wang M, Xiong D, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and Cosmc. Mol Med Rep. 2017;15(2):969–74.CrossRef
5.
go back to reference Qin W, Zhou Q, Yang LC, et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin a nephropathy. J Intern Med. 2005;258(5):467–77.CrossRef Qin W, Zhou Q, Yang LC, et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin a nephropathy. J Intern Med. 2005;258(5):467–77.CrossRef
6.
go back to reference Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30(8):1315–21.CrossRef Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30(8):1315–21.CrossRef
7.
go back to reference Ofek SN, Rao S, Patole S. Efficacy of interventions to improve hand hygiene compliance in neonatal units: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2015;34(5):887–97.CrossRef Ofek SN, Rao S, Patole S. Efficacy of interventions to improve hand hygiene compliance in neonatal units: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2015;34(5):887–97.CrossRef
8.
go back to reference Shao JW. IL-4,C1GALT1 and COSMC Expression in Severe IgA Nephropathy and the Prognosis Analysis of the Disease. Labeled Immunoassays Clin Med 2016 .23(12): 1375–1378. Shao JW. IL-4,C1GALT1 and COSMC Expression in Severe IgA Nephropathy and the Prognosis Analysis of the Disease. Labeled Immunoassays Clin Med 2016 .23(12): 1375–1378.
9.
go back to reference Cai Y, Jiang XY, Chen SM, et al. Expression of β1,3 Galactosyltransferase mRNA and Cosmc mRNA in peripheral B lymphocyte of patients with IgA nephropathy. J Appl Clin Pediatr. 2010;25(16):1254–6. Cai Y, Jiang XY, Chen SM, et al. Expression of β1,3 Galactosyltransferase mRNA and Cosmc mRNA in peripheral B lymphocyte of patients with IgA nephropathy. J Appl Clin Pediatr. 2010;25(16):1254–6.
10.
go back to reference Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int. 2008;73(10):1128–36.CrossRef Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int. 2008;73(10):1128–36.CrossRef
11.
go back to reference Boyd FJK. Glycosyltransferase expression in IgA+ B cells in IgA nephropathy; 2014. Boyd FJK. Glycosyltransferase expression in IgA+ B cells in IgA nephropathy; 2014.
12.
go back to reference Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12(4):701–6.CrossRef Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12(4):701–6.CrossRef
13.
go back to reference McCluer R, Koul O. Glycosyltransferase inhibitors and study of UDP-galactose-globoside galactosyltransferase. Biokhimiia. 1995;60(3):419–31.PubMed McCluer R, Koul O. Glycosyltransferase inhibitors and study of UDP-galactose-globoside galactosyltransferase. Biokhimiia. 1995;60(3):419–31.PubMed
14.
go back to reference Inoue T, Sugiyama H, Hiki Y, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010;136(3):447–55.CrossRef Inoue T, Sugiyama H, Hiki Y, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010;136(3):447–55.CrossRef
15.
go back to reference Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25(12):3890–7.CrossRef Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25(12):3890–7.CrossRef
16.
go back to reference Novak J, Raskova KL, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant. 2011;26(11):3451–7.CrossRef Novak J, Raskova KL, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant. 2011;26(11):3451–7.CrossRef
17.
go back to reference Xie LS, Qin W, Fan JM, Huang J, Xie XS, Li Z. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clin Invest Med. 2010;33(1):E5–13.CrossRef Xie LS, Qin W, Fan JM, Huang J, Xie XS, Li Z. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clin Invest Med. 2010;33(1):E5–13.CrossRef
18.
go back to reference Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A. 2002;99(26):16613–8.CrossRef Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A. 2002;99(26):16613–8.CrossRef
Metadata
Title
C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy
Authors
Yue Xing
Lina Li
Yaru Zhang
Fanghao Wang
Dandan He
Youxia Liu
Junya Jia
Tiekun Yan
Shan Lin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1675-5

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine